Fluorouracil News and Research

RSS
Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

Myriad Genetics OnDose collection kit eliminates need for frozen sample handling

Myriad Genetics OnDose collection kit eliminates need for frozen sample handling

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris commences perifosine Phase 3 registration trial

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation